Global Anti-Fibrotic Therapy For Ocular Fibrosis Market Size By Type (Injection, Oral), By Application (Hospital, Eye Clinic), By Geographic Scope And Forecast

Anti-Fibrotic Therapy for Ocular Fibrosis Market Size And Forecast

Anti-Fibrotic Therapy for Ocular Fibrosis Market size is valued at USD 1.82 Billion in the year 2021 and it is expected to reach USD 2.47 Billion in 2030 at a CAGR of 4.13% over the forecast period of 2023 to 2030.

Anti-fibrotic therapy for ocular fibrosis is being pushed by several causes, including the demand for effective treatments, the rising incidence of ocular fibrosis, and advances in healthcare technology and research. The Global Anti-Fibrotic Therapy for Ocular Fibrosis Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Definition

Anti-fibrotic therapy for ocular fibrosis comprises a class of treatments aimed at reducing fibrous tissue production and buildup in the eye. Fibrosis is a frequent reaction to damage or chronic inflammation in which extracellular matrix parts, such as collagen, are deposited, causing scarring and hardening of the tissue. Fibrosis in the eye may develop in various tissues, including the cornea, conjunctiva, retina, and optic nerve, and can result in blurred vision and other consequences.

Anti-fibrotic treatment for ocular fibrosis is available in various forms involving surgical, pharmacological, and biological techniques. Mitomycin C, a chemotherapeutic medication that suppresses cell proliferation and collagen formation, is one of the most often utilized anti-fibrotic treatments in ophthalmology. Mitomycin C is often used to minimize postoperative scarring and enhance surgical results after glaucoma or cataract surgery.

Pirfenidone, a tiny molecule that suppresses the synthesis of converting growth factor-beta (TGF-beta), a critical mediator of fibrosis, is an additional anti-fibrotic medication that has shown potential in managing ocular fibrosis. Pirfenidone’s ability to decrease scarring and inflammation in the eye has been explored in animal models and clinical studies. It may have been used to manage corneal scarring, conjunctival fibrosis, and proliferative vitreoretinopathy.

Another growing field of anti-fibrotic treatment for ocular fibrosis is biological medicines. Monoclonal antibodies that target TGF-beta, including fresolimumab and SAR439459, are one example of such treatment. These antibodies inhibit TGF-beta activity and have shown potential in early clinical studies in managing fibrotic illnesses such as ocular fibrosis.

Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Overview

Ocular fibrosis is a typical complication that can arise during ocular procedures, including glaucoma, cataract, and retinal detachment surgery, as well as as a result of ocular disorders, including diabetic retinopathy as well as age-associated macular degeneration. One critical stimulus for anti-fibrotic treatment for ocular fibrosis is the rising incidence of ocular fibrosis. This is because the aging population is likelier to have eye disorders that might lead to fibrosis. The frequency of ocular fibrosis is predicted to rise as the population ages, creating a greater need for effective therapies.

Advances in medical science and studies are also driving anti-fibrotic treatment for ocular fibrosis. As the awareness of the molecular processes behind fibrosis has grown, likewise has the development of novel medicines that target particular pathways implicated in the pathogenesis of ocular fibrosis. TGF-beta, for instance, was recently identified as a critical route in the growth of ocular fibrosis. As a result, medications targeting this route, including pirfenidone and fresolimumab, have shown promising results in preclinical as well as preliminary clinical trials.

Furthermore, progress has been made in the advancement of surgical techniques for the therapy of ocular fibrosis. Tissue-engineered implants and stem cell treatments are being explored to restore or repair injured eye tissue and avoid fibrous tissue growth. These advances in surgical procedures have created new treatment options for ocular fibrosis and stimulated the development of novel medicines. However, the high cost of novel medications constitutes one of the primary impediments. Developing novel anti-fibrotic medicines is costly and time-consuming, and research and regulatory clearance costs can be substantial. Consequently, the cost of such therapies might be prohibitively expensive, rendering them less available to patients who cannot afford them.

 Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Anti-Fibrotic Therapy for Ocular Fibrosis Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in Global Anti-Fibrotic Therapy for Ocular Fibrosis Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Global Anti-Fibrotic Therapy for Ocular Fibrosis Market Segmentation Analysis

The Global Anti-Fibrotic Therapy for Ocular Fibrosis Market is Segmented on the Basis of Type, Application, And Geography.

Anti-Fibrotic Therapy for Ocular Fibrosis Market, By Type

• Injection
• Oral

Based on Type, the market is segmented into Oral, Injection. The injection segment held a significant market share in the Anti-Fibrotic Therapy for Ocular Fibrosis Market in 2021. In recent years, the injectable segment of anti-fibrotic treatment for ocular fibrosis has witnessed significant growth in demand. Injectables are used for ocular fibrosis therapy because they may be administered directly to the afflicted region, offering a more specific and efficient treatment. Furthermore, injectables have an extended period of action that may decrease treatment frequency and enhance patient adherence. Injection anti-fibrotic treatment for ocular fibrosis includes medications including Lucentis, Avastin, and Eylea.

Anti-Fibrotic Therapy for Ocular Fibrosis Market, By Application

• Hospital
• Eye Clinic

Based on Application, the market is segmented into Hospital and Eye Clinic. The hosital segment dominated the global Anti-Fibrotic Therapy for Ocular Fibrosis Market with the highest market share in 2021. Anti-fibrotic treatment for ocular fibrosis is a significant market in hospitals. Hospitals are the primary site for healthcare for individuals with ocular fibrosis, and they are essential to the disease’s evaluation, therapy, and treatment. Hospitals additionally serve as the primary reference source for patients needing specialized treatment, such as anti-fibrotic treatment. The rising incidence of ocular fibrosis and increased knowledge of the advantages of anti-fibrotic therapy are projected to drive up the need for anti-fibrotic therapy in the healthcare sector in the future years.

Anti-Fibrotic Therapy for Ocular Fibrosis Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of Geography, the Global Anti-Fibrotic Therapy for Ocular Fibrosis Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Asia Pacific region accounted for the highest market share in the global Anti-Fibrotic Therapy for Ocular Fibrosis Market in the year 2021. The existence of significant companies, favorable reimbursement circumstances, and the rising frequency of ocular fibrosis are some of the factors influencing its substantial share. Furthermore, rising awareness of sophisticated treatment alternatives will likely boost development during the projection period.

Key Players

The “Global Anti-Fibrotic Therapy for Ocular Fibrosis Market” study report will provide valuable insight with an emphasis on the global market including some of the major players of the industry are Novartis International AG, Allergan, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Sanofi S.A., Promedior Inc., Bausch Health Companies Inc., Bristol Myers Squibb Co., Galapagos NV, FibroGen Inc., Biogen Inc., Genzyme Corporation, Boehringer Ingelheim International GmbH, Pfizer Inc., AbbVie Inc., among others.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In April 2021, Santen Pharmaceutical Co. Ltd. reported that its anti-fibrotic medication, EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, had been approved by the European Commission for the management of ocular inflammation and discomfort following cataract surgery.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Report Scope

Top Trending Reports

Research Methodology of Market Research